To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer
A Prospective, open, randomized, controlled clinical study to evaluate the efficacy and safety of PEG-rhG-CSF(PEGylated recombinant human granulocyte stimulating factor injection) in reducing neutropenia during TP(docetaxel+cisplatin) regiment simultaneous radiochemotherapy and adjuvant chemotherapy in patients with cervical cancer
Cervical Cancer
DRUG: PEG-rhG-CSF|DRUG: rhG-CSF
Incidence of III/IV neutropenia, The incidence of III/IV neutropenia in each chemotherapy cycle, 3 months
Incidence of FN, Incidence of febrile neutropenia (FN) in each chemotherapy cycle, 3 months|Proportion of chemotherapy dose adjustment, Proportion of chemotherapy dose adjustment due to neutropenia, 3 months
A Prospective, open, randomized, controlled clinical study to evaluate the efficacy and safety of PEG-rhG-CSF(PEGylated recombinant human granulocyte stimulating factor injection) in reducing neutropenia during TP(docetaxel+cisplatin) regiment simultaneous radiochemotherapy and adjuvant chemotherapy in patients with cervical cancer